Epilepsy affects around 50 million people in the world, therefore improving treatment efficacy and safety for epileptics is imperative. In this study we sought to screen the effectiveness and safety of cannabis constituents (delta-9-tetrahydrocannabinol and cannabidiol) and Tapinanthus globiferus extracts in treating epilepsy. We used a zebrafish model wherein seizures were induced by treatment with pentylenetetrazol. Our results showed that Tapinanthus globiferus dose-dependently reduced seizure activity, and no toxicities were seen at the concentrations used. In contrast delta-9-tetrahydrocannabinol and cannabidiol did not significantly reduce seizure activity and some toxicities were seen at the higher concentrations tested. We conclude that extracts of Tapinanthus globiferus show promise as anticonvulsants and further research is needed to identify the active constituents and their pharmacological properties
